stockrow
Friday 6 November 2026
Export AMPH’s income statement to Excel — free account
Amphastar Pharmaceuticals, Inc.
AMPH Healthcare Drug Manufacturers Specialty & Generic
Amphastar Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.9 million, down 1.65% from fiscal 2024.
- Revenue
- +8.22%
- EPS
- +134.2%
- Free cash flow
- −29.4%
- Total debt
- +0.57%
Quarter to September 2026, against a year earlier
27.59
0.43
−1.53%
Follow AMPH
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
11.47 | 11.60 | 11.46 | 12.75 |
+8 more quarters Free account |
P/S ratio |
1.47 | 1.21 | 1.23 | 1.74 | |
P/FCF ratio |
8.04 | 5.85 | 6.69 | 10.53 | |
P/Operating CF |
25.38 | 17.16 | 18.56 | 38.09 | |
P/B ratio |
1.35 | 1.15 | 1.15 | 1.59 | |
Price to Tangible BV |
6.31 | 7.32 | 4.15 | 5.62 | |
EV/Sales |
1.90 | 1.64 | 1.67 | 2.19 | |
EV/EBITDA |
8.12 | 6.87 | 6.79 | 7.87 | |
EV/Operating CF |
8.10 | 6.50 | 7.14 | 10.10 | |
EV/FCF |
10.39 | 7.98 | 9.07 | 13.27 | |
Quick Ratio |
0.00 | 1.67 | 2.75 | 2.82 | |
Current Ratio |
3.32 | 2.40 | 3.85 | 4.02 | |
Net Debt/EBITDA |
0.00 | 5.82 | 11.03 | 6.40 | |
Debt/Assets |
35.81% | 35.10% | 37.10% | 37.46% | |
Debt/Equity |
0.75 | 0.80 | 0.79 | 0.77 | |
Asset Turnover |
0.44 | 0.43 | 0.44 | 0.45 | |
Operating CF/Net income |
1.15 | 1.69 | 7.45 | 1.35 | |
Capex/Depreciation |
0.00 | (0.57) | (0.63) | (0.54) | |
Interest Coverage |
7.51 | 5.97 | 2.08 | 5.37 | |
Research and Development Expense of Revenue |
9.67% | 12.05% | 15.62% | 12.73% | |
Selling, General and Administrative Expense of Revenue |
13.86% | 17.17% | 17.50% | 14.61% | |
Intangible Assets out of Total Assets |
0.37 | 0.37 | 0.34 | 0.35 | |
Share Based Compensation of Revenue |
3.38% | 3.86% | 5.42% | 3.39% | |
Graham Net Nets |
(0.27) | (0.39) | (0.27) | (0.16) | |
Graham Number |
31.12 | 26.25 | 25.62 | 28.24 | |
Earnings Yield |
8.72% | 8.62% | 8.73% | 7.84% | |
Free Cash Flow Yield |
12.43% | 17.09% | 14.96% | 9.49% | |
Revenue per Share |
4.88 | 4.21 | 3.78 | 3.92 | |
Operating CF per Share |
1.02 | 1.18 | 1.06 | 0.70 | |
Capex per Share |
(0.23) | (0.20) | (0.21) | (0.18) | |
Free Cash Flow per Share |
0.78 | 0.98 | 0.85 | 0.53 | |
Cash per Share |
0.00 | 6.70 | 6.50 | 6.10 | |
Shareholders Equity per Share |
19.13 | 17.60 | 17.06 | 16.88 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
19.13 | 17.60 | 17.06 | 16.88 | |
Free Cash Flow |
33.36 | 42.73 | 38.33 | 24.59 | |
Working Capital |
421.25 | 367.75 | 469.21 | 477.86 | |
Capital Expenditures |
(9.94) | (8.59) | (9.51) | (8.27) | |
Net Current Asset Value |
(294.48) | (344.66) | (241.09) | (204.48) | |
EV/EBIT |
10.16 | 10.50 | 10.32 | 11.23 | |
Capex to Sales |
0.05 | 0.05 | 0.06 | 0.05 | |
Price to Operating Income |
7.86 | 7.71 | 7.61 | 8.92 | |
| Other line items | |||||
Average Receivables |
— | 141.04 | 151.42 | 149.38 | |
Average Payables |
179.46 | 208.96 | 164.31 | 152.70 | |
Average Inventory |
179.93 | 185.82 | 177.84 | 165.32 | |
Average Assets |
1,688.97 | 1,679.55 | 1,637.22 | 1,603.38 | |
Average Common Equity |
795.65 | 762.82 | 762.34 | 760.55 |
Columns are period end dates · fundamentals updated 5 Nov 2026